Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) EVP Jamie Christensen sold 1,531 shares of the stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $58.81, for a total transaction of $90,038.11. Following the transaction, the executive vice president now directly owns 157,135 shares of the company’s […]
StockNews.com started coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note published on Friday. The brokerage issued a sell rating on the biotechnology company’s stock. Several other analysts have also recently issued reports on MRTX. Stifel Nicolaus reaffirmed a hold rating and issued a $59.00 price target (down from $83.00) […]
StockNews.com began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX – Free Report) in a research note released on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Other research analysts have also recently issued research reports about the company. Jefferies Financial Group cut Mirati Therapeutics from a buy rating to a […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) was the target of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 4,740,000 shares, a decrease of 22.2% from the November 15th total of 6,090,000 shares. Based on an average trading volume of 2,270,000 shares, […]
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Free Report) EVP Benjamin Hickey sold 2,220 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $56.67, for a total value of $125,807.40. Following the transaction, the executive vice president now owns 103,694 shares of […]